Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Ann Cardiol Angeiol (Paris) ; 67(3): 127-132, 2018 Jun.
Article in French | MEDLINE | ID: mdl-29753420

ABSTRACT

OBJECTIVES: To compare a so-called an "accelerated" antihypertensive strategy to a "standard" strategy, in terms of blood pressure control rates and adverse events. METHODS: Prospective open-label randomized controlled trial, which included consecutive hypertensive patients, newly diagnosed, 40 to 70 years old, with no prior antihypertensive treatment. Hypertension was diagnosed if office blood pressure was≥140/90mmHg, confirmed by an increase of Home or a daytime ambulatory blood pressure. The patients were randomly assigned according to 1:1 ratio to an "accelerated" strategy or to a "standard" strategy. The primary end-point was the rate of blood pressure control at 12weeks. The secondary end-point was the rate of adverse events (a safety end-point). RESULTS: We recruited 268 patients (132 in the "accelerated" strategy group), with a mean age of 55 years and 62% of men. The mean office blood pressure at baseline was 168/95mmHg. The clinical characteristics were on average similar between the 2 treatment groups. At 12 weeks, the rates of blood pressure control were 63.6% in the "accelerated" strategy and 38.2% in the "standard" strategy (P<0.001). There was no significantly difference between the rates of adverse events in the 2 strategies (6.06% versus 5.14%; P=0.8). CONCLUSION: The "accelerated" antihypertensive strategy was more effective than a standard one, in terms of blood pressure control, without an increase in adverse events rate. This could translate into a future cardiovascular events reduction.


Subject(s)
Antihypertensive Agents/administration & dosage , Hypertension/drug therapy , Adult , Aged , Antihypertensive Agents/adverse effects , Blood Pressure , Female , Humans , Hypertension/physiopathology , Male , Middle Aged , Prospective Studies , Time Factors , Treatment Outcome
2.
Ann Cardiol Angeiol (Paris) ; 65(3): 191-6, 2016 Jun.
Article in French | MEDLINE | ID: mdl-27180567

ABSTRACT

OBJECTIVES: Estimate the prevalence of resistant hypertension (rHTN) in uncontrolled hypertensive treated patients referred to a tertiary care center specialized for hypertension management. METHODS: The study was prospective observational. Between January 2013 and April 2015, we recruited hypertensive treated patients, 18years age or older, under antihypertensive drugs since at least 12months, and referred to the hypertension unit of Tizi-ouzou university hospital for uncontrolled hypertension. rHTn was defined as an office blood pressure≥140mmHg despite a triple therapy including renin angiotensin system blockers, calcium antagonists and diuretics at optimal doses, since at least 4weeks. RESULTS: We screened 2367 patients with a mean age of 61.1±11.2years and 64.2% of men. Eight hundred forty-three (35.6%) patients had suboptimal treatment, 364 (15.4%) a poor adherence to treatment and 202 (8.5%) a white-coat effect. An excessive salt intake and a drug-related hypertension were identified in 281 (11.9%) and 36 (1.5%) patients, respectively. A secondary cause of hypertension was diagnosed in 468 (19.8%) subjects. Finally, only 173 patients showed a true rHTN requiring four drugs or more and its prevalence was 7.3% (CI 95%: 6.3-8.3). CONCLUSION: Less than one patient from ten referred in our center for uncontrolled hypertension had a true rHTN, and more than fifty percent of patients had pseudo-resistance. Most of patients with seemingly rHTN can reach blood pressure target provided they undergo thorough work up and care by a specialized team.


Subject(s)
Blood Pressure Determination/statistics & numerical data , Blood Pressure , Hypertension/epidemiology , Tertiary Care Centers/statistics & numerical data , Aged , Algeria/epidemiology , Antihypertensive Agents/therapeutic use , Blood Pressure/drug effects , Blood Pressure Monitoring, Ambulatory/statistics & numerical data , Calcium Channel Blockers/therapeutic use , Diuretics/therapeutic use , Drug Therapy, Combination , Female , Humans , Hypertension/drug therapy , Male , Middle Aged , Prevalence , Prospective Studies , Renin-Angiotensin System/drug effects , Risk Factors
SELECTION OF CITATIONS
SEARCH DETAIL
...